pcsk 9

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) is a secretory subtilase belonging to the proteinase K subfamily. PCSK9 is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the ER , the pro domain and mature chain secrete together through noncovalent interactions. PCSK9 binds with low-density lipoprotein receptor (LDLR) and plays a major regulatory role in cholesterol homeostasis. PCSK9 also plays a role in the neural development.

Proprotein convertase subtilisin kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.

Expression system: HEK293 Cells
Length: 31-692 (mutation), Full Length of Mature Protein
Activity: Not Tested

Expression system: HEK293 Cells
Length: 31-692 (mutation), Full Length of Mature Protein
Activity: Not Tested

Expression system: HEK293 Cells
Length: 31-692, Full Length of Mature Protein
Activity: BLI、Octet RED、ELISA